BioSpace News Archive

Kineta, Inc. (Nasdaq: KA) announced today that two abstracts have been accepted for poster presentation on Kineta’s immuno-oncology therapies at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting to be held November 1-5, 2023, in San Diego, California and virtually.

PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced updated Phase 1 results from its ongoing Phase 1/2 PYNNACLE clinical trial that showed PC14586 achieved efficacy in heavily pretreated patients across multiple tumor types and was well tolerated with a favorable safety profile.

Virpax ® Pharmaceuticals, Inc. today announced that the cooperative research and development agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) to evaluate Virpax’s Probudur™, an injectable long-acting liposomal bupivacaine formulation that is injected at the wound site, has been extended to September of 2024.

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its third-quarter financial results on Thursday, Nov. 2, 2023.

RespireRx Pharmaceuticals Inc. are pleased to announce that on October 9, 2023, ResolutionRx entered into a Master Services Agreement (“MSA”) with Ab Initio Pharma Pty Ltd.

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced the publication of two cases of long-term disease-free survival in the treatment of advanced hepatocellular carcinoma (HCC) with CARsgen’s innovative CAR-GPC3 T-cell therapy.

Centinel Spine®, LLC, (“the Company”) today announced that it will highlight the new prodisc Match-the-Disc™ cervical and lumbar TDR systems at the upcoming North American Spine Society (NASS) 38th Annual Meeting in Los Angeles, CA (October 18-21, 2023).

Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company based in Japan, will share new research that advances understanding about the real-world experiences and clinical characteristics of children, adolescents, and adults living with X-linked hypophosphatemia (XLH), a rare genetic metabolic bone disease.

ICON plc, a world-leading healthcare intelligence and clinical research organization, announced that S&P Global Ratings upgraded ICON to an investment grade credit rating of BBB- with a stable outlook, based on operating performance and deleveraging.

GE HealthCare announced it signed a $44 million contract with the Biomedical Advanced Research and Development Authority —part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services —to develop and obtain regulatory clearance for next-generation advanced point-of-care ultrasound technology with new artificial intelligence applications.